Although the involvement of other genes or signaling pathways in cisplatin-induced cachexia in bladder cancer cannot be overlooked, the components of the EGFR-ProT-NF-κB-HOTAIR signaling axis represent targets for novel therapeutic strategies to prevent or ameliorate cisplatin-induced cachexia in bladder cancer and other cancers. Here, EGFR is linked to urinary bladder carcinoma.